Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.79
-0.26 (-4.30%)
At close: Jul 16, 2025, 4:00 PM
6.13
+0.34 (5.87%)
After-hours: Jul 16, 2025, 7:38 PM EDT
Coya Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Coya Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $16.5, which forecasts a 184.97% increase in the stock price over the next year. The lowest target is $14 and the highest is $18.
Price Target: $16.5 (+184.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coya Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +176.34% | Jul 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +141.80% | Jul 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +210.88% | Jun 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +141.80% | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +141.80% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
4.32M
from 3.55M
Increased by 21.49%
Revenue Next Year
2.35M
from 4.32M
Decreased by -45.67%
EPS This Year
-1.58
from -0.98
EPS Next Year
-1.89
from -1.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.6M | 10.5M | 15.8M | ||
| Avg | 4.3M | 2.3M | 8.5M | ||
| Low | 252,840 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 168.8% | 143.2% | 571.4% | ||
| Avg | 21.5% | -45.7% | 262.3% | ||
| Low | -92.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.78 | -1.51 | -0.68 | ||
| Avg | -1.58 | -1.89 | -1.33 | ||
| Low | -1.86 | -2.26 | -2.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.